Meeting
2012 ASCO Annual Meeting
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy.
Authors
Martin H. Schuler
Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany
Martin H. Schuler , David Planchard , James Chih-Hsin Yang , Joo-Hang Kim , Filippo De Marinis , Yuh-Min Chen , Caicun Zhou , Jaafar Bennouna , Xiaoqing Liu , Ji Feng Feng , Paolo Bidoli , Janos Strausz , Sai-Hong Ignatius Ou , Vikram K. Chand , Bushi Wang , Gerd Michael Munzert , Keunchil Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01085136
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7557)
DOI
10.1200/jco.2012.30.15_suppl.7557
Abstract #
7557
Poster Bd #
46G
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2017 ASCO Annual Meeting
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
First Author: Joop De Langen
Poster
2016 ASCO Annual Meeting
HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.
First Author: Bing Xia
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu